IRIS
ROMANO, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.299
EU - Europa 2.808
AS - Asia 1.809
AF - Africa 354
SA - Sud America 260
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 10.537
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.139
IT - Italia 1.169
SG - Singapore 1.080
IE - Irlanda 700
CN - Cina 562
UA - Ucraina 394
CI - Costa d'Avorio 271
BR - Brasile 238
CA - Canada 149
RU - Federazione Russa 140
DE - Germania 116
SN - Senegal 61
SE - Svezia 54
VN - Vietnam 54
FI - Finlandia 48
GB - Regno Unito 45
IN - India 26
FR - Francia 23
NL - Olanda 23
BE - Belgio 22
CZ - Repubblica Ceca 19
JP - Giappone 15
CH - Svizzera 12
HK - Hong Kong 12
UZ - Uzbekistan 12
AR - Argentina 9
GR - Grecia 9
PL - Polonia 9
NG - Nigeria 8
AT - Austria 7
KR - Corea 7
LB - Libano 7
MA - Marocco 7
MX - Messico 5
TR - Turchia 5
AU - Australia 4
IL - Israele 4
NO - Norvegia 4
RO - Romania 4
BD - Bangladesh 3
CO - Colombia 3
DO - Repubblica Dominicana 3
EC - Ecuador 3
EU - Europa 3
IR - Iran 3
PY - Paraguay 3
ZA - Sudafrica 3
AL - Albania 2
AZ - Azerbaigian 2
ID - Indonesia 2
JO - Giordania 2
KZ - Kazakistan 2
LU - Lussemburgo 2
PH - Filippine 2
PK - Pakistan 2
RS - Serbia 2
SA - Arabia Saudita 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
BH - Bahrain 1
BO - Bolivia 1
CL - Cile 1
DK - Danimarca 1
DZ - Algeria 1
EG - Egitto 1
ES - Italia 1
HN - Honduras 1
IQ - Iraq 1
KE - Kenya 1
LK - Sri Lanka 1
LT - Lituania 1
PA - Panama 1
SC - Seychelles 1
SI - Slovenia 1
SV - El Salvador 1
TH - Thailandia 1
Totale 10.537
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.101
Dublin 693
Singapore 652
Chandler 587
Jacksonville 448
Chicago 417
Houston 366
Boardman 295
Catania 272
Abidjan 271
Ashburn 196
Lawrence 145
Cambridge 144
Nanjing 139
Andover 138
Toronto 114
Civitanova Marche 113
Florence 104
Des Moines 72
San Mateo 62
Dakar 61
Rome 54
Wilmington 53
Nanchang 46
Dong Ket 45
Saint Petersburg 42
Beijing 41
Washington 39
Hebei 36
Milan 34
Helsinki 33
Los Angeles 32
Tianjin 31
Ottawa 30
Shenyang 30
Grafing 29
Munich 27
New York 24
Jiaxing 21
Brussels 20
Council Bluffs 20
São Paulo 20
Bremen 19
Palermo 19
Changsha 18
Seattle 17
Lappeenranta 15
Messina 15
Moscow 14
Bernareggio 12
Brno 12
Bronte 12
Hong Kong 12
Guangzhou 11
Misterbianco 11
Falls Church 10
Dearborn 9
Genoa 9
Hanoi 9
Norwalk 9
Pune 9
Abuja 8
Amsterdam 8
Den Haag 8
Fukuoka 8
Hangzhou 8
Turin 8
Hanover 7
Seoul 7
Tokyo 7
Edinburgh 6
Naples 6
Redwood City 6
Zhengzhou 6
Augusta 5
Kunming 5
Liberty Lake 5
Livorno 5
Mascalucia 5
Mumbai 5
Nuremberg 5
Paris 5
Porto Alegre 5
Aachen 4
Acerra 4
Aci Catena 4
Ann Arbor 4
Bari 4
Belo Horizonte 4
Campinas 4
Castiglione di Sicilia 4
Chieti 4
Forcoli 4
Frankfurt Am Main 4
Gela 4
Giarre 4
Jinan 4
Lausanne 4
Ludwigshafen 4
Oslo 4
Totale 7.545
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 231
Childhood neurofibromatosis type 2 (NF2) and related disorders: From bench to bedside and biologically targeted therapies [Neurofibromatosi tipo 2 (NF2) e sindromi correlate in età infantile: dalla biologia molecolare alla pratica clinica e nuove terapie con farmaci biologici] 215
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload 159
Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. 131
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 124
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 110
"MESENTERIUM COMMUNE" IN GIOVANE ADULTO. UN RARO CASO CLINICO 103
Focus on Osteosclerotic Progression in Primary Myelofibrosis 98
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 93
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 93
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 90
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen 89
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells 88
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM) 87
Mesenchymal stem cells (MSC) promotes tumor microenvironment transformation driving Granulocyte-like Myeloid Derived Suppressor Cells (G-MDSC) activation in Smoldering and Multiple Myeloma patients 87
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. 86
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 86
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 84
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 81
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 81
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 79
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 78
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 77
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 76
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 75
A snapshot of asparaginase-induced liver insufficiency. 74
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 74
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 74
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 73
Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma (Cell Death & Disease, (2019), 10, 10, (704), 10.1038/s41419-019-1959-5) 73
Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes 72
Hedgehog signaling pathways in multiple myeloma 71
Bone turnover markers in patients with type 1 Gaucher disease 71
A Reciprocal Link between Oral, Gut Microbiota during Periodontitis: The Potential Role of Probiotics in Reducing Dysbiosis-Induced Inflammation 70
SMOLDERING MYELOMA: WALKING THROUGH RISK FACTORS AND TENTATIVE CLASSIFICATION SYSTEMS 69
HIGH-RESOLUTION SNP ARRAYS AS AN ADDITIONAL TOOL TO SEARCH FOR GENETIC DEFECTS INVOLVED IN PROGRESSION FROM MYELODYSPLASTIC SINDROME TO ACUTE LEUKEMIA 69
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 69
NEUTROPHIL TO LYMPHOCYTE RATIO IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 69
Rate of fungal infections in patients with acute myeloid leukemia during induction treatment performing two prophylactic strategies: preliminary results 69
Detection of fungal dna in lysis-centrifugation blood culture for the prevision of response to antifungal in aml patients with persistent neutropenic fever: a pilot subset 69
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 68
ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN'S LYMPHOMA 68
Bortezomib for the treatment of previously untreated multiple myeloma. 67
IMATINIB INCREASES CYTOTOXICITY OF MELPHALAN AND DECREASES PROLONGATION OF G2-M PHASE IN HUMAN K562 CELLS 66
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients 65
Bortezomib induced expression of heme oxygenase 1 via endoplasmic reticulum stress 19th Congress of the European-Hematology-Association. Milan, ITALY. Jun 12-15, 2014. 65
HS-TROPONINE T RELATES WITH MYOCARDIAL IRON OVERLOAD IN TRANSFUSION DEPENDENT THALASSEMIC PATIENTS 64
CIRCULATING ARGINASE-1 IN SERUM IS A NOVEL BIO-MARKERIN HODGKIN LYMPHOMA 64
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 64
BROAD COPY NEUTRAL-LOSS OF HETEROZYGOSITY REGIONS AND RARE RECURRING COPY NUMBER ABNORMALITIES IN KARYOTYPICALLY NORMAL ACUTE MYELOID LEUKEMIA GENOMES 64
CD200 EXPRESSION ON MYELOMA CELLS AND ANTITUMOR IMMUNITY 63
The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents 63
A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents 63
Immunological deregulation in classic hodgkin lymphoma. 62
Single segment of spleen autotransplantation, after splenectomy for trauma, can restore splenic functions 62
The Role of Dielectrophoresis for Cancer Diagnosis and Prognosis 62
CD200 expression in patients with multiple myeloma: Another piece of the puzzle 61
Clinical impact of the immunome in lymphoid malignancies: the role of Myeloid-Derived Suppressor Cells 60
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 59
BROAD COPY NEUTRAL-LOSS OF HETEROZYGOSITY REGIONS AND RARE RECURRING COPY NUMBER ABNORMALITIES IN KARYOTYPICALLY NORMAL ACUTE MYELOID LEUKEMIA GENOMES 59
Proteomic analysis reveals autophagy as pro-survival pathway elicited by long-term exposure with 5-azacitidine in high-risk myelodysplasia 59
MONOCYTIC MYELOID DERIVED SUPPRESSOR CELLS (M-MDSC) AS PROGNOSTIC FACTOR IN DASATINIB TREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA 59
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 58
Standard therapies versus novel therapies in Hodgkin lymphoma. 58
Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib 58
The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma 58
MYELOID DYSFUNCTION IN SICKLE CELL DISEASE 58
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 57
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases 57
GRANULOCYTE-LIKE MYELOID DERIVED SUPPRESSOR CELLS ARE INCREASED IN MULTIPLE MYELOMA DUE TO IMMUNOLOGICAL DYSREGULATION OF MESENCHYMAL STEM CELLS 57
IN MULTIPLE MYELOMA THERE ARE TWO SUBSETS OF IMMUNOSUPPRESSIVE POLYMORPHONUCLEAR NEUTROPHILS WITH INCREASED LEVELS OF ARGINASE 57
Bone Turnover Markers In Gaucher Disease Patients 57
Troponine T as a marker of cardiac impairment in patients suffering thalassemia 57
Carbon nanotube-based sensing devices for human Arginase-1 detection 57
The Effect of the Interaction between Proton Pump Inhibitors (PPI) and Tyrosine Kinase Inhibitors (Imatinib, Nilotinib and Dasatinib) 56
Analysis of metabolic parameters coming from basal and interim PET in hodgkin lymphoma 56
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 56
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study 56
UP-REGULATION OF PROK-2/BV8 IN GRANULOCYTES IS PRESENT BOTH IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND MULTIPLE MYELOMA 55
THE ROLE OF SPARC IN CHRONIC MYELOID LEUKEMIA 55
Somatic CNVs and LOH in Acute Myelomonocitic Leukemia 54
The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma. 54
Serum free light chains and multiple myeloma: Is it time to extend their application? 54
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis 54
Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview 54
Heme oxygenase 1 (HO-1) protects myeloma cells against bortezomib through nuclear translocation and regulation of ER stress and autophagy proteins. 53
Acute GVHD after allogeneic hematopoietic transplantation affects early marrow reconstitution and speed of engraftment 52
Rare gastrointestinal lymphomas: the endoscopic investigation 52
OVEREXPRESSION OF ARGINASE AND PROK-2 MAKES NEUTROPHILS OF MULTIPLE MYELOMA DYSFUNCTIONAL AND IMMUNOSUPPRESSIVE 52
Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma. 52
A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones? 52
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 51
MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes 50
Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up 50
LACK OF ACTIVITY OF LENALIDOMIDE ON OSTEOBLASTS 50
Plasmocytosis and Immunoparesis but Not Neutrophil to Lymphocyte Ratio Can Predict Time to Treatment in Smoldering Myeloma 49
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over 48
Le leucemie acute mieloidi a cariotipo normale non sono caratterizzate da instabilita` genomica 48
Myeloid-Derived Suppressor Cells in Patients with Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance 48
Treatment with TKIs Overcomes Imatinib Resistance through the PLCgamma-1 Signaling Pathway In Imatinib Resistant Human CML Cell Lines 47
Totale 7.101
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.478
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.478
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020130 0 0 0 0 0 0 0 0 0 0 87 43
2020/2021871 17 61 96 36 229 19 118 10 88 9 106 82
2021/20221.115 115 154 8 11 193 21 156 60 107 16 33 241
2022/20232.145 160 116 31 132 232 366 9 371 532 35 108 53
2023/20241.347 59 195 74 108 70 296 31 105 9 32 218 150
2024/20253.875 57 742 290 216 952 510 150 208 342 385 23 0
Totale 10.848